 | |
| Clinical data | |
|---|---|
| Trade names | Scemblix |
| Other names | ABL001 |
| License data | |
| Pregnancy category | |
| Routes of administration | By mouth |
| Drug class | Tyrosine kinase inhibitor |
| ATC code | |
| Legal status | |
| Legal status | |
| Identifiers | |
| |
| CAS Number |
|
| PubChem CID | |
| IUPHAR/BPS | |
| DrugBank | |
| ChemSpider | |
| UNII |
|
| KEGG | |
| ChEMBL |
|
| PDB ligand | |
| Chemical and physical data | |
| Formula | C20H18ClF2N5O3 |
| Molar mass | 449.84 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Asciminib, sold under the brand name Scemblix, is a medication used to treat Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML).[5][7][8] Asciminib is a protein kinase inhibitor.[5]
The most common adverse reactions include upper respiratory tract infections, musculoskeletal pain, fatigue, nausea, rash, and diarrhea.[7]
Asciminib was approved for medical use in the United States in October 2021,[5][9][10][11] and in the European Union in August 2022.[6]
YouTube Encyclopedic
-
1/5Views:3 3628581 042440333
-
Asciminib: overcoming TKI resistance and reducing toxicity in CML
-
The use of asciminib versus ponatinib for multiresistant CML
-
Fourth generation TKIs for CML: asciminib
-
Asciminib and bosutinib efficacy in CML-CP patients: a comparison study
-
Targeting TKI-resistant CML with LY3009120 and asciminib
Transcription
Mechanism of action
Asciminib is described as a "STAMP inhibitor," which means "specifically targeting the ABL myristoyl pocket." The wild-type ABL has a myristoylated N-terminus, which binds to an allosteric site, but the ABL fusion protein does not have the myristoylated domain. In the wild-type protein, when myristoylated N-terminus binds to the allosteric site, the kinase has reduced activity. Since the mutant fusion protein does not have the myristoylated N-terminus domain, it is not subject to this form of regulation, and thus the fusion protein is constitutively active. Asciminib binds to the allosteric site, resulting in an inhibition of bcr-abl activity.[12]
Unlike other bcr-abl inhibitors, such as imatinib, asciminib does not bind to the ATP-binding site on the active site of the enzyme. Asciminib and active site bcr-abl inhibitors have non-overlapping resistance mutations. The mutations A337V and P223S overcome the inhibitory activity of asciminib,[13] but asciminib is not affected by the notorious T315I mutation that affects most ATP-competitive active site inhibitors, except ponatinib.
Adverse effects
Common side effects of Asciminib are symptoms of a cold, muscle pain, joint pain, bone pain, fatigue, nausea, diarrhea, rash as well as the patient displaying abnormal blood tests.[14] Serious side effects of the medication include high blood pressure, low blood cell count, problems with the pancreas, and heart issues.[14] Side effects of the medication on the pancreas may be observed via changes in serum lipase and amylase levels.[15]
Pharmacodynamics
Asciminib is a substrate of the CYP3A4 enzyme.[15] Asciminib is an inhibitor of CYP3A4, CYP2C9, and P-glycoprotein.[15] Asciminib reaches steady state in 3 days. The volume of distribution of Asciminib is 151 L.[15]
History
The FDA approved asciminib based on evidence from a clinical trial of 48 participants with chronic myeloid leukemia with a certain type of mutation (T315I mutation).[9] The trial was conducted at 18 sites in ten countries (Australia, France, Germany, Italy, Japan, Netherlands, the Republic of Korea, Singapore, Spain, and the United States).[9] Participants received asciminib twice daily until disease worsened or unacceptable toxicity occurred.[9] The benefit of asciminib was evaluated in Philadelphia chromosome-positive chronic myeloid leukemia participants with the T315 mutation by measuring the reduction of abnormal cells in participants' blood to a very low level after 96 weeks of treatment.[9]
Society and culture
Legal status
On 23 June 2022, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion, recommending the granting of a marketing authorization for the medicinal product Scemblix, intended for the treatment of adults with Philadelphia chromosome‑positive chronic myeloid leukemia in chronic phase who have previously been treated with two or more tyrosine kinase inhibitors.[16] The applicant for this medicinal product is Novartis Europharm Limited.[16] Asciminib was approved for medical use in the European Union in August 2022.[6][17]
The US Food and Drug Administration (FDA) granted the application for asciminib priority review, fast track, orphan drug, and breakthrough therapy designations.[7][18][19][20]
References
- ^ a b "Scemblix APMDS". Therapeutic Goods Administration (TGA). 26 July 2022. Archived from the original on 2 August 2022. Retrieved 2 August 2022.
- ^ "Updates to the Prescribing Medicines in Pregnancy database". Therapeutic Goods Administration (TGA). 21 December 2022. Archived from the original on 3 April 2022. Retrieved 2 January 2023.
- ^ "Scemblix Product information". Health Canada. 25 April 2012. Archived from the original on 1 October 2022. Retrieved 30 September 2022.
- ^ "Details for: Scemblix". Health Canada. 1 September 2022. Archived from the original on 3 March 2024. Retrieved 3 March 2024.
- ^ a b c d "Scemblix- asciminib tablet, film coated". DailyMed. Archived from the original on 5 November 2021. Retrieved 4 November 2021.
- ^ a b c "Scemblix EPAR". European Medicines Agency (EMA). 20 June 2022. Archived from the original on 9 September 2022. Retrieved 8 September 2022. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
- ^ a b c This article incorporates text from this source, which is in the public domain.
- ^ Breccia M, Colafigli G, Scalzulli E, Martelli M (August 2021). "Asciminib: an investigational agent for the treatment of chronic myeloid leukemia". Expert Opinion on Investigational Drugs. 30 (8): 803–811. doi:10.1080/13543784.2021.1941863. PMID 34130563. S2CID 235450899.
- ^ a b c d e This article incorporates text from this source, which is in the public domain.
- ^ "Drug Approval Package: Scemblix". U.S. Food and Drug Administration (FDA). 24 November 2021. Retrieved 2 June 2023.
- ^ "FDA approves Novartis Scemblix (asciminib), with novel mechanism of action for the treatment of chronic myeloid leukemia". Novartis (Press release). Archived from the original on 29 October 2021. Retrieved 29 October 2021.
- ^ Schoepfer J, Jahnke W, Berellini G, Buonamici S, Cotesta S, Cowan-Jacob SW, et al. (September 2018). "Discovery of Asciminib (ABL001), an Allosteric Inhibitor of the Tyrosine Kinase Activity of BCR-ABL1". Journal of Medicinal Chemistry. 61 (18): 8120–8135. doi:10.1021/acs.jmedchem.8b01040. PMID 30137981. S2CID 52073282.
- ^ Jones JK, Thompson EM (September 2020). "Allosteric Inhibition of ABL Kinases: Therapeutic Potential in Cancer". Molecular Cancer Therapeutics. 19 (9): 1763–1769. doi:10.1158/1535-7163.MCT-20-0069. PMC 7484003. PMID 32606014.
- ^ a b "Asciminib Uses, Side Effects & Warnings". Drugs.com. Archived from the original on 21 June 2022. Retrieved 21 June 2022.
- ^ a b c d "Scemblix (asciminib) dosing, indications, interactions, adverse effects, and more". reference.medscape.com. Archived from the original on 2 August 2022. Retrieved 27 June 2022.
- ^ a b "Scemblix: Pending EC decision". European Medicines Agency. 23 June 2022. Archived from the original on 26 June 2022. Retrieved 26 June 2022. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
- ^ "Scemblix Product information". Union Register of medicinal products. Archived from the original on 3 March 2023. Retrieved 3 March 2023.
- ^ "Asciminib Orphan Drug Designations and Approvals". U.S. Food and Drug Administration (FDA). 27 February 2017. Archived from the original on 29 October 2021. Retrieved 29 October 2021.
- ^ "Novartis receives FDA Breakthrough Therapy designations for investigational STAMP inhibitor asciminib (ABL001) in chronic myeloid leukemia". Novartis (Press release). 8 February 2020. Archived from the original on 29 October 2021. Retrieved 29 October 2021.
- ^ This article incorporates text from this source, which is in the public domain.
External links
- Clinical trial number NCT02081378 for "A Phase I Study of Oral ABL001 in Patients With CML or Ph+ ALL" at ClinicalTrials.gov
- Clinical trial number NCT03106779 for "Study of Efficacy of CML-CP Patients Treated With ABL001 Versus Bosutinib, Previously Treated With 2 or More TKIs" at ClinicalTrials.gov
This page was last edited on 10 March 2024, at 06:42